BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29777523)

  • 21. Dual-time-point
    Hoberück S; Wunderlich G; Michler E; Hölscher T; Walther M; Seppelt D; Platzek I; Zöphel K; Kotzerke J
    J Labelled Comp Radiopharm; 2019 Jun; 62(8):523-532. PubMed ID: 31042811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection efficacy of PET/CT with
    Otani T; Saga T; Ishimori T; Kidera E; Shimizu Y; Aizawa R; Nakamura K; Goto T; Akamatsu S; Mizowaki T; Nakamoto Y
    Ann Nucl Med; 2022 Mar; 36(3):302-309. PubMed ID: 35064537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
    Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of
    Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective correlation of
    Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
    Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
    Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
    Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
    J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
    [No Abstract]   [Full Text] [Related]  

  • 33.
    van Boxtel W; Lütje S; van Engen-van Grunsven ICH; Verhaegh GW; Schalken JA; Jonker MA; Nagarajah J; Gotthardt M; van Herpen CML
    Theranostics; 2020; 10(5):2273-2283. PubMed ID: 32089741
    [No Abstract]   [Full Text] [Related]  

  • 34. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
    Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A
    Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Liu T; Liu C; Zhang Z; Zhang N; Guo X; Xia L; Jiang J; Xie Q; Yan K; Rowe SP; Zhu H; Yang Z
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4508-4516. PubMed ID: 34170361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical performance of
    Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of 5th minute and 2nd hour images to standard imaging in (
    Can C; Komek H
    Ann Nucl Med; 2020 Mar; 34(3):163-173. PubMed ID: 31808135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodistribution and radiation dosimetry of [
    Hohberg M; Kobe C; Krapf P; Täger P; Hammes J; Dietlein F; Zlatopolskiy BD; Endepols H; Wild M; Neubauer S; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    EJNMMI Res; 2019 Jul; 9(1):66. PubMed ID: 31346821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.